AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05264220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Matrix
Description: Participants will receive a 4 session psychological intervention based on the ACT Matrix
Study NCT06163677 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Receipt of Pfizer BioNTech COVID-19 vaccine
Study NCT05023369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg/ml)
Description: Dexamethasone will be administered as an injectable solution (4mg/ml). Every ml of this solution contains 4 mg of dexamethasone sodium phosphate, corresponding to 3 mg of dexamethasone. Thus 3 ml of solution will be injected peri-articularly (arm-A)
Study NCT04894461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: The moxibustion treatment sessions are three times per week for eight weeks. Indirect moxa stick will be used.
Study NCT06138223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: During 12 weeks, patients will visit twice a week a trained oncology physiotherapist for one hour per session. This training includes supervised aerobic and resistance exercises to increase aerobic condition and muscle resistance, based on their own fitness level as assessed at baseline. Additionally, physiotherapists will educate participants on how to increase their daily activity. To this end, all participants will receive an activity tracker to monitor their daily activities.
Study NCT06138223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Description: Once every two weeks patients in the intervention group will receive a nutritional assessment and intervention by a trained dietician for optimization of their nutritional intake to improve their nutritional status, following the ESPEN guideline on nutrition in cancer patients and the national guidelines of the National Nutritionists Oncology Working Group (NNOWG; in Dutch: Landelijke Werkgroep Diëtisten Oncologie, LWDO). Moreover, an amount of 15-25 grams of protein within 1-2 hours after exercise will be advised, to prevent muscle protein breakdown and enhance muscle protein synthesis.
Study NCT05581901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone (Dose1)
Description: Dose: 0.10mg/kg
Study NCT05581901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone (Dose 2)
Description: Dose: 0.15mg/kg
Study NCT05581901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone (Dose 3)
Description: Dose 0.20mg/kg
Study NCT05555173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: Buzzy is a small vibrating bee with ice-pack wings.
Study NCT05015413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave
Description: Shock wave master 500 Germany
Study NCT04987944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant
Description: 150 mg BID
Study NCT04987944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching active drug
Study NCT05421884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 Love Languages
Description: Emotional support will be given through utilizing the patient/partners specific Love Language (physical touch, words of affirmation, gifts, quality time, and acts of service).
Study NCT05277480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib+IE
Description: apatinib po； ifosfamide ivgtt ; etoposide ivgtt .
Study NCT05277480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IE
Description: ifosfamide ivgtt ; etoposide ivgtt .
Study NCT05207189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UVT
Description: Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator.
Study NCT04801407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous radiofrequency trigeminal rhizotomy
Description: percutaneous radiofrequency trigeminal rhizotomy is a perctaneous procedure that ablate the sensory part of the nerve and
Study NCT04801407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microvascular decompression of the trigeminal nerve
Description: Microvascular decompression is a procedure that decompress the nerve from vascular conflict
Study NCT05760716 — intervention group
Intervention type: OTHER
Intervention: practicing prone position
Description: Wash your hands. Prepare the materials. Before starting the procedure, inform the patient and explain the procedure. Ensure patient privacy. Raise the guardrail opposite the work area. Take the proper posture. Pay attention to body mechanics. Lay the patient on their back in the middle of the bed. Place a pillow under the patient's head to cover their shoulders. Extend arms to side of body with elbows slightly bent inward (flexion). Place a pillow under your arms. Place roller in palm. Place a thin pillow or a thinly folded towel/sheet under the waist. Place a thin towel under the knees. Support the bottom of the ankles with a pillow. Support the soles of the feet with a foot board. Raise the guardrail on the working side. Inform the patient that they can stay in this position for a maximum of 2 hours.
Study NCT04572009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio-mathematical model
Description: bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
Study NCT04572009 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Without bio-mathematical model
Description: No bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
Study NCT05930015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention only
Description: Music only (120-130 bpm) The effect was achieved by playing music selected by the researchers during originally physical education classes in school; twice a week for eight weeks
Study NCT05930015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sports games intervention only
Description: Sports games intervention only The effect was achieved by replacing the school's originally physical education classes with sports games of the researchers' choice; twice a week for eight weeks
Study NCT05930015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music and sports games intervention
Description: Music and sports games intervention, the effect was achieved by replacing the school's physical education classes with sports games of the researchers' choice, and then by playing music of the researchers' choice during class; twice a week for eight weeks
Study NCT04037241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CEA CAR-T cells
Description: Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device
Study NCT04037241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine/nab paclitaxel
Description: systemic chemotherapy regimen
Study NCT04037241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/nab paclitaxel
Description: systemic chemotherapy regimen
Study NCT04037241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NLIR+FU/FA
Description: systemic chemotherapy regimen
Study NCT04037241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NLIR+FU/FA
Description: systemic chemotherapy regimen
Study NCT04037241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: systemic chemotherapy regimen
Study NCT04037241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: systemic chemotherapy regimen
Study NCT04026568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Aminopyridine
Description: Single drug test for nerve continuity
Study NCT04026568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo arm
Study NCT05699655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 4 cycles. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
Study NCT05699655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Participants will receive apatinib, 250mg, qd，every 3 weeks for 3 weeks
Study NCT05699655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.
Study NCT05699655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.
Study NCT05699655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.
Study NCT05699655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.
Study NCT04899479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
Study NCT04899479 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
Study NCT05147675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT05684640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rodatristat Ethyl
Description: Tablets, Oral, 600mg, QD
Study NCT05684640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rodatristat Ethyl
Description: Tablets, Oral, 600mg, QD
Study NCT05684640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0mg, BID
Study NCT05063903 — intervention group
Intervention type: OTHER
Intervention: Demographic and clinical characteristics, incremental shuttle walk test, six minute walk test, hand grip strength, M. Quadriceps isometric muscle strength, body composition
Description: Demographic and clinical characteristics Age and complaints, post-operative follow-up, other problems, medications, ECHO and ECG findings, laboratory tests (complete blood count, liver and kidney function tests, brain natriuretic peptide (BNP) level)~Hand grip strength Right and left hand grip strength the highest of the three measurements~Lower extremity muscle strength Maximum isometric muscle strength of the quadriceps femoris~Body composition Body fat ratio, lean body weight and fat weight by bioelectrical impedance analysis~6 minute walk test The six minute walk test distance recorded in meters~Incremental shuttle walk test The lap number, the number of laps of the last level they can reach, and the walking/running distances recorded in meters
Study NCT05473585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low nicotine content cigarettes
Description: Investigational combusted cigarettes with very low nicotine content
Study NCT05473585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal nicotine content cigarettes
Description: Investigational combusted cigarettes with normal nicotine content
Study NCT05473585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study e-cigarette
Description: E-cigarette provided by study
Study NCT05473585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study e-cigarette
Description: E-cigarette provided by study
Study NCT04725357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Description: Participants will receive a prescription of 20 pills of 15 mg Meloxicam after surgery
Study NCT04725357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative Interscalene Nerve Block
Description: Preoperatively participants will standardly receive an interscalene nerve block
Study NCT04725357 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Interscalene Nerve Block
Description: Preoperatively participants will standardly receive an interscalene nerve block
Study NCT04725357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic labral repair
Description: participant will have their standard surgical procedure done
Study NCT04725357 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic labral repair
Description: participant will have their standard surgical procedure done
Study NCT05424432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: Paclitaxel (135 mg /m2) and carboplatin (AUC=5) every 3 weeks for two cycles (D1,D22)
Study NCT06220695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: The dietary intervention is a personalized counselling programme implemented in form of a moderate caloric restriction (≈500 kcal/day) to allow for a moderate weight loss (≈5% BW). Each participant will be invited for consultation visits to a study dietitian, lasting up to 30 minutes. During the sessions, participants will be provided with written information material that explains the principles of diet in concern. Dietary interventions for both groups will be standardized in terms of education and one-on-one counseling. Education and dietary prescription will be individualized by the study dietitians within the diet-specific recommendations, to allow for personal food preferences. All subjects will receive equivalent intensity of care in terms of opportunities for contact and availability of individual dietary counseling. Motivational interviewing techniques and behavior change techniques will be adopted by study dietitians to ensure long-term maintenance of dietary modification.
Study NCT06220695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The dietary intervention is a personalized counselling programme implemented in form of a moderate caloric restriction (≈500 kcal/day) to allow for a moderate weight loss (≈5% BW). Each participant will be invited for consultation visits to a study dietitian, lasting up to 30 minutes. During the sessions, participants will be provided with written information material that explains the principles of diet in concern. Dietary interventions for both groups will be standardized in terms of education and one-on-one counseling. Education and dietary prescription will be individualized by the study dietitians within the diet-specific recommendations, to allow for personal food preferences. All subjects will receive equivalent intensity of care in terms of opportunities for contact and availability of individual dietary counseling. Motivational interviewing techniques and behavior change techniques will be adopted by study dietitians to ensure long-term maintenance of dietary modification.
Study NCT06033729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil TCI
Description: REMI-TCI administration begun 5 minutes before the procedure, starting from an initial target at the effect site of 1 ng/ml and gradually increasing by 0.5 ng/ml until reaching an adequate level of sedation (Ramsey score between 2-3).
Study NCT04914962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glazed zirconium lithium silicate
Description: monolithic glazed crown
Study NCT04914962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polished zirconium lithium silicate
Description: monolithic polishedcrowns
Study NCT04742790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Scalp electroencephalography (EEG)
Description: Resting EEG will be recorded before initiation of the combination treatment (visit 1) and 7-10 days after treatment (visit 2). Drug-induced sedation-related changes in the EEG frequency spectrum. Five minutes of resting EEG eyes-open will be recorded in a quiet room while participants are asked to focus on an image displayed on a wall. Then, they will be asked to close their eyes for an additional 2 minutes. The alpha power ratio eyes open/eyes closed will be computed (alpha attenuation coefficient; Kaida et al., 2006). Changes in this coefficient will be used as a measure of drug-induced sedation.
Study NCT04742790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laser-evoked potentials (LEPs)
Description: Laser-evoked potentials (LEPs) will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short pulses (50-100 ms) of radiant heat generated by a C02 laser stimulator will be applied to the skin of the left or right hand dorm to briefly and selectively activate heat-sensitive pain receptors. A concomitant EEG recordings will be used to measure the amplitude and latency of the elicited laser-evoked potentials. Changes in LEP amplitude (expressed as percentage of change) will be used as a measure of drug-induced effects on the state of the thermonociceptive system.
Study NCT06033729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: Bolus administration of midazolam (1-2 mg)and/or until a Ramsey score 2-3 was reached
Study NCT06033729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Bolus adminitration of fentanyl (50-100 mcg) until a Ramsey score 2-3 was reached
Study NCT06033729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Bolus adminitration of propofol until a Ramsey score 2-3 was reached
Study NCT06044363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satir group
Description: Participants in the intervention group will receive a 10-session, 3-hour/session intervention that spans over a period of five days (2 sessions/day). The intervention program will be conducted on specific weekends, with a gap of 1 to 2 weeks. The total duration of the intervention will be 30 hours.
Study NCT04742790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognitive auditory-evoked potentials (P300)
Description: Cognitive auditory-evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short-lasting auditory tones will be delivered using a three-stimulus oddball paradigm combining standard tones (90% of stimuli), slightly different target tones that the subject must attend and detect (10% of stimuli), and strongly different distractor non-target tones (10% of stimuli). The stimuli will be delivered binaurally using headphones. Participants will be instructed to press a button when they detect a target tone, and to ignore the standard and distractor non-target tones. The EEG recordings will be used to measure the amplitude and latency of the cognitive P3a and P3b potentials (Komerchero \& Polich 1999). Changes in P3a/P3b amplitude will be used as a measure of drug-induced effects on cognition (expressed as percentage of change).
Study NCT04742790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cervical somatosensory-evoked potentials
Description: Cervical spinal-cord evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. The responses will be elicited by transcutaneous electrical stimulation of the median nerve. The N13 component of this response is mediated by large myelinated non-nociceptive fibers and reflects a segmental postsynaptic response of dorsal horn interneurons at the level of lumbar spinal cord (Cruccu et al., 2008). Changes in magnitude of the N13 will be used as a measure of drug-induced effects on spinal cord function (expressed as percentage of change).
Study NCT04742790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: Pupillometry measurements will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Pupillometry has been proposed as a method to assess opioid pharmacodynamics. The extent of pupil dilatation can provide an index of nociceptive input via autonomic innervation of the iris muscles, while the extent of the attenuation of this pupillary response during exposure to opioid analgesics could provide an index of pharmacological effects reflecting the extent of opioid receptor occupancy in the CNS. Pupillometry (static pupil diameter, variability of pupil diameter \[variation coefficient of pupillary dilation, VCPD, Charier et al. 2017\]), light-evoked speed of pupil constriction \[maximum pupil constriction velocity, PCV, Connely et al., 2014\]) will be measured using a handheld pupillometry device routinely used for clinical evaluations.
Study NCT04742790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saccadic Peak Velocity
Description: The saccadic peak velocity (SPV; m/s) will be measured before before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Saccadic peak velocity is one of the most sensitive parameters for sedation. Recording of eye movements will be performed in a quiet room with dimmed lightning. Average values of saccadic peak velocity (expressed as degrees/second) of all correct saccades will be measured.
Study NCT04742790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Adaptive tracking test
Description: The test will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Adaptive tracking is a pursuit-tracking task sensitive to impairment of eye-hand coordination by drugs. It has been proven useful for measuring CNS effects of alcohol, various other psychoactive drugs, and sleep deprivation.